Annexon Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Annexon hat ein Gesamteigenkapital von $262.4M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $304.1M bzw. $41.7M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$368.70m
Eigenkapital	US$361.08m
Gesamtverbindlichkeiten	US$45.01m
Gesamtvermögen	US$406.09m

Jüngste Berichte zur Finanzlage

Recent updates

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Sep 27

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Aug 17

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 04

Annexon: Unforced Error Sullies Prospects

Apr 03

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

Nov 10

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Jul 25

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Apr 11

Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

Feb 14

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Dec 28

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Sep 16

Annexon: A First Take

Aug 21

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Aug 08

Annexon to raise $130M in stock and warrant offering

Jul 08

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Apr 16

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Jan 01

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Sep 08

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

May 22

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Feb 06

Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome

Dec 21

Annexon Biosciences EPS misses by $0.43

Nov 16

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ANNXDie kurzfristigen Aktiva des Unternehmens ($270.7M) übersteigen seine kurzfristigen Passiva ($13.1M).

Langfristige Verbindlichkeiten: ANNXDie kurzfristigen Vermögenswerte des Unternehmens ($270.7M) übersteigen seine langfristigen Verbindlichkeiten ($28.5M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ANNX ist schuldenfrei.

Schulden abbauen: ANNX hat keine Schulden im Vergleich zu vor 5 Jahren, als das Verhältnis von Schulden zu Eigenkapital 13.6% betrug.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: ANNX auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: ANNX über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt, wenn der freie Cashflow weiterhin mit historischen Raten von 32.6% pro Jahr zurückgeht

Annexon Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Recent updates

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Annexon, Inc. Announces Management Appointments

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Annexon, Inc. Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Price target increased by 13% to US$16.40

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Annexon, Inc. Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

New major risk - Share price stability

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Annexon, Inc. Presents New Neuro Protection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy

Annexon, Inc., Annual General Meeting, Jun 05, 2024

Annexon: Unforced Error Sullies Prospects

Price target increased by 9.0% to US$15.17

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Insider selling

New major risk - Share price stability

Executive VP notifies of intention to sell stock

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

New major risk - Revenue and earnings growth

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

New minor risk - Market cap size

Price target increased by 10% to US$15.60

New major risk - Revenue and earnings growth

Price target increased by 9.0% to US$15.33

Annexon, Inc. Appoints Jamie Dananberg as Chief Medical Officer

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Price target decreased by 18% to US$15.43

Annexon, Inc. Announces Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

Annexon, Inc. Highlights Strategic Focus to Advance Four Complement Programs Through Late-Stage Development and Progress Across Three Therapeutic Franchises

Annexon, Inc. Announces Executive Changes

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Price target decreased to US$18.71

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Annexon: A First Take

Price target decreased to US$24.25

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Annexon, Inc. announced that it has received $130.475296 million in funding from a group of investors

Annexon, Inc. announced that it expects to receive $130.475296 million in funding from a group of investors

Annexon to raise $130M in stock and warrant offering

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Index

Annexon, Inc. Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’S Disease

Price target decreased to US$30.80

CEO, President & Director recently bought US$147k worth of stock

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Price target decreased to US$30.80

Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

Price target decreased to US$34.20

Annexon, Inc. Announces Resignation of Sanjay Keswani as Executive Vice President and Chief Medical Officer

Annexon, Inc. Announces Resignation of Ricky Sun as Board Member

Annexon, Inc. Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition

CEO, President & Director exercised options to buy US$1.5m worth of stock.

Executive VP & Chief Scientific Officer Ted Yednock has left the company

Executive VP & Chief Scientific Officer exercised options and sold US$297k worth of stock

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon, Inc Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Growth Index

Executive VP & CFO exercised options and sold US$52k worth of stock

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Annexon, Inc. Announces Executive Changes

Independent Director has left the company

New 90-day high: US$33.04

Independent Director has left the company